Aytu BioPharma Inc. Announces Merger with Rosemont Pharmaceuticals and Reports Strong Q1 2027 Results

Aytu BioPharma Inc. (NASDAQ: AYTU) announced on November 16, 2026 that it had entered into a definitive merger agreement with Rosemont Pharmaceuticals Holdings, Inc. The all‑cash tender offer values each Aytu share at $2.70, representing a 41.1 % premium over the 30‑day volume‑weighted average price and a 51.7 % premium over the closing price on November 13, 2026.

Merger Details

  • Purchase price: $2.70 per share in cash.
  • Premiums: 41.1 % over 30‑day VWAP; 51.7 % over November 13 closing price.
  • Support: Tender‑offer support agreements have been secured from Nantahala Capital Management, Stonepine Capital Management, and Aytu’s directors and officers.
  • Closing: Expected by the end of 2026, contingent on satisfaction or waiver of tender‑offer conditions.

The transaction is positioned to accelerate Rosemont’s U.S. expansion and to strengthen its specialty‑pharmaceutical portfolio with Aytu’s established ADHD platform and emerging major depressive disorder (MDD) asset.

Financial Performance for Fiscal 2027 Q1

Aytu reported operational and financial results for the quarter ended September 30, 2026, covering the first quarter of fiscal 2027.

MetricQ1 FY2027Q1 FY2026YoY Change
Net revenue$14.8 million$13.9 million+6.9 %
EXXUA net revenue$4.9 million$3.9 million (Q4 FY2026)+24.5 %
Total prescriptions4,400–+32.5 % sequentially
ADHD portfolio net revenue$7.7 million$13.2 million (Q1 FY2026)–

Aytu’s GAAP earnings per share for the quarter was –$0.20, a beat of $0.14 over analysts’ expectations. Revenue of $14.84 million surpassed forecasts by $1.57 million.

Market Reaction

Following the merger announcement, Aytu shares surged 44 % in after‑hours trading on November 17, 2026, reflecting investor optimism about the strategic fit and premium offered by Rosemont. The stock closed at $1.82 on November 15, 2026, down slightly from the 52‑week high of $3.07 set on January 4, 2026, and above the 52‑week low of $1.75 recorded on November 15, 2026.

Company Background

Aytu BioPharma Inc. specializes in the acquisition, development, and commercialization of products targeting sexual dysfunction disorders, urological cancer, urinary tract infections, and male infertility. The company’s operations are globally oriented, with a focus on central nervous system (CNS) diseases such as ADHD and MDD. Aytu is listed on the Nasdaq stock exchange and has a market capitalization of approximately $19.3 million.


This article summarizes the key points of Aytu BioPharma’s recent merger announcement, its financial performance for the latest fiscal quarter, and the immediate market response.